Navigation Links
Manufacturer Halts Production of Blood Thinner Heparin
Date:2/11/2008

Drug linked to hundreds of allergic reactions and possibly 4 deaths, FDA says

MONDAY, Feb. 11 (HealthDay News) -- Baxter HealthCare Corp., which produces half of the blood thinner heparin sold in the United States, said Monday that it was temporarily suspending production of its multi-dose injectable form of the drug following reports of serious allergic reactions and possibly four patient deaths.

The cause of the allergic reactions isn't known. It's also not clear how long production will be stopped. The one thing that is clear is that the stoppage could lead to a shortage of heparin, which is used to prevent blood clots in such patients as those undergoing kidney dialysis and heart surgery, U.S. health officials said.

Since the end of December, there have been about 350 reports of adverse reactions associated with Baxter's heparin product. This compares with less than 100 reports of adverse reactions in all of 2007, Dr. John Jenkins, director of the U.S. Food and Drug Administration Office of New Drugs at the Center for Drug Evaluation and Research, said during a Monday teleconference.

Most of the reactions have taken place at hemodialysis centers, almost exclusively involving patients receiving a "bolus dose," which is a high dose administered over a short period of time, the FDA said.

"While we have reports of four deaths at this time, it is not possible to establish a relationship between the deaths and the use of heparin," Jenkins said. "To date, a cause to the adverse events has not been identified."

Adverse reactions included difficulty breathing, nausea or vomiting, excessive sweating and falling blood pressure, which can lead to life-threatening shock. These reactions have been seen with as few as several thousand units per milliliter of heparin, and as much as 50,000 units per milliliter, Jenkins said.

Most of the reactions have taken place in patients receiving high doses of heparin before undergoing dialysis or heart surgery. The problem was first reported to the U.S. Centers for Disease Control and Prevention in January by the Missouri Department of Health and Senior Services, which had seen several cases in one pediatric hospital starting in November, the FDA said.

The CDC alerted the FDA and Baxter, which started a voluntary recall of the affected lots of heparin Jan. 17. Since that time, however, adverse reactions have been found in other lots of Baxter's multi-dose heparin, which led to Monday's suspension of production.

"FDA is currently collaborating with Baxter, the CDC and other experts to determine the root cause of the serious adverse events," Jenkins said. "Investigators and scientists are conducting inspections of all facilities and processes involved in the manufacture of Baxter's heparin. FDA investigators and scientists are also conducting tests of samples of Baxter's product."

Baxter's suspension of production of multi-dose vials of heparin could lead to a shortage of the drug, Jenkins said. "The FDA is working with other manufacturers of heparin to fill the void that will occur if the Baxter manufacturing suspension continues," he said.

It's not clear how long production will be stopped, so doses of Baxter's multi-dose heparin already in the hands of hospitals and clinics will not be recalled, Jenkins said.

"A recall would result in an immediate and severe shortage of this medically necessary drug. FDA has concluded that it is better for the public health to allow the Baxter multiple dose vials of heparin to remain in distribution," Jenkins said.

More than one million multiple-dose vials of heparin are sold each month in the United States.

A prepared statement released Monday by Baxter said: "Given the widespread use of this critical anticoagulant (frequently called a blood thinner) and the impact a product shortage would have on operating rooms, dialysis centers and other critical care areas, the removal of Baxter's heparin from the market would create more risk to the population of patients requiring heparin therapy than the increased potential for experiencing an adverse reaction."

Baxter, which is based in Deerfield, Ill., will continue to make its single dose vials of heparin. Adverse events like the ones associated with the multiple dose vials have been reported in a few cases when single dose vials were combined to give a single large dose to a patient, Jenkins said.

The other approved manufacturer of multiple dose vials of heparin, APP Pharmaceuticals of Schaumburg, Ill., is also being checked to see if there has been an increase in the number of adverse reactions with its product, Jenkins said. At this time, APP products have not been associated with these adverse events, he said.

Until the cause of the adverse reactions is known, the FDA is advising doctors to give large doses of heparin through intravenous infusion whenever possible. Doctors should also give the lowest dose at the slowest rate of infusion possible, and patients should be monitored for any sign of an adverse event, Jenkins said.

More information

For more on heparin, visit the U.S. National Library of Medicine.



SOURCES: Baxter HealthCare Corp., Deerfield, Ill., news release; Feb. 11, 2008, teleconference with John Jenkins, M.D., director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Rockville, Md.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. AUDIO From Medialink and the National Association of Margarine Manufacturers: Survey Finds Americans Unaware Some Fats Are Good for Heart Health
2. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
3. Patient Lift Manufacturer, Medcare Products, Obtains Women-Owned Certification
4. PCMA Statement on New Average Manufacturer Price (AMP) Legislation
5. Visiprise Launches Podcast Series with AMR to Support Medical Device Manufacturers
6. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
7. Experimental Vaccine Halts Prostate Cancer in Mice
8. Scripps research scientists find new genetic mutation that halts the development of lupus
9. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
10. Two Little Hands Productions, Creators of Popular Childrens TV Series Signing Time, Debuts Second Season at This Years Toy Fair 2008
11. Elephant Ensemble Theater Brings New Production to Bronx Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: